(EMAILWIRE.COM, November 20, 2018 ) Cell encapsulation technology enables to overcome the existing issue of graft rejection in tissue engineering applications. It helps to minimize the requirement for long-term use of immuno-suppressive drugs after an organ transplant in order to control side effects. This technology is also known as Cell-in-a-Box. It enables to encapsulate cells in cellulose based, beads, with a semipermeable membrane that allow nutrients and waste product exchange, however, retains the cells within the beads.

The global live cell encapsulation technology market is estimated to grow at a high rate during the forecast period. A number of factors such as increasing incidence of various types of cancers (such as pancreatic, breast, and brain), rising prevalence of diabetes, and rising adoption of cell encapsulation technology to develop treatments for cancer and diabetes are fuelling the growth of the global live cell encapsulation technology market.

Get Free PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218019375

Live Cell Encapsulation Technology Market, By Application:
Biotechnology
Healthcare
Research
Agriculture
Cosmetics
Environmental
Alginate

Austrianova Singapore Pte Ltd (Singapore), Beta-Cell NV (Belgium), Cellmed AG (Germany), Cerco Medical (U.S.), Living Cell Technologies Limited (New Zealand), Neurotech Pharmaceuticals, Inc. (Rhode Island), NovaMatrix (Norway) are some of the key players in the global live cell encapsulation technology market.

Request Free Sample Pages Of Industry Insights:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=218019375